AssayQuant
Private Company
Total funding raised: $2.5M
Overview
AssayQuant is a specialized provider of continuous enzyme activity assays and profiling services, primarily focused on kinases and phosphatases for the drug discovery market. Founded in 2010, the company's proprietary PhosphoSens® Technology uses fluorescent sensor peptides to generate real-time progress curves, revealing inhibitor dynamics, reversibility, and mechanism of action. Its business model combines the sale of assay kits and reagents with fee-for-service profiling, supporting pharmaceutical and biotech clients from target validation through lead optimization. By delivering kinetic data traditionally missed by endpoint reads, AssayQuant aims to enable faster, more data-rich decision-making in preclinical development.
Technology Platform
PhosphoSens® Technology: A platform using fluorescent sensor peptide substrates for continuous, real-time measurement of kinase and phosphatase activity, generating kinetic progress curves to reveal inhibitor dynamics and mechanism of action.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
AssayQuant competes in the biochemical assay market against large vendors like Promega (ADP-Glo), PerkinElmer, and Revvity, as well as specialized CROs offering profiling services. Its key differentiation is the provision of continuous, real-time kinetic data versus standard endpoint reads. It competes on data richness and mechanistic insight rather than scale or price alone.